Abstract
Opicapone (OPC), a once-daily catechol-O-methyltransferase inhibitor, proved to be effective in treating end-of-dose motor fluctuations in Parkinson's disease (PD) patients in two large multinational trials. We evaluated the efficacy of OPC in PD patients with motor fluctuation according to levodopa's duration of use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
